tetano
Editor, Senior Moderator
Cell Commun Signal
. 2024 Jun 3;22(1):305.
doi: 10.1186/s12964-024-01680-0. STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy
Aysa Rezabakhsh[SUP] 1 [/SUP], M Reza Sadaie[SUP] 2 [/SUP], Alireza Ala[SUP] 3 [/SUP], Yousef Roosta[SUP] 4 [/SUP], Solomon Habtemariam[SUP] 5 [/SUP], Adeleh Sahebnasagh[SUP] 6 [/SUP], Mohammad Rafi Khezri[SUP] 7 [/SUP]
Affiliations
As a major component of innate immunity and a positive regulator of interferons, the Stimulator of interferon gene (STING) has an immunotherapy potential to govern a variety of infectious diseases. Despite the recent advances regarding vaccines against COVID-19, nontoxic novel adjuvants with the potential to enhance vaccine efficacy are urgently desired. In this connection, it has been well-documented that STING agonists are applied to combat COVID-19. This approach is of major significance for boosting immune responses most likely through an autophagy-dependent manner in susceptible individuals against infection induced by severe acute respiratory syndrome Coronavirus (SARS‑CoV‑2). Given that STING agonists exert substantial immunomodulatory impacts under a wide array of pathologic conditions, these agents could be considered novel adjuvants for enhancing immunogenicity against the SARS-related coronavirus. Here, we intend to discuss the recent advances in STING agonists' recruitment to boost innate immune responses upon vaccination against SARS-related coronavirus infections. In light of the primordial role of autophagy modulation, the potential of being an antiviral vaccine adjuvant was also explored.
Keywords: Autophagy; COVID-19; Immunogenicity; SARS-CoV-2; Stimulator of interferon gene; Vaccine adjuvant.
. 2024 Jun 3;22(1):305.
doi: 10.1186/s12964-024-01680-0. STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy
Aysa Rezabakhsh[SUP] 1 [/SUP], M Reza Sadaie[SUP] 2 [/SUP], Alireza Ala[SUP] 3 [/SUP], Yousef Roosta[SUP] 4 [/SUP], Solomon Habtemariam[SUP] 5 [/SUP], Adeleh Sahebnasagh[SUP] 6 [/SUP], Mohammad Rafi Khezri[SUP] 7 [/SUP]
Affiliations
- PMID: 38831299
- DOI: 10.1186/s12964-024-01680-0
As a major component of innate immunity and a positive regulator of interferons, the Stimulator of interferon gene (STING) has an immunotherapy potential to govern a variety of infectious diseases. Despite the recent advances regarding vaccines against COVID-19, nontoxic novel adjuvants with the potential to enhance vaccine efficacy are urgently desired. In this connection, it has been well-documented that STING agonists are applied to combat COVID-19. This approach is of major significance for boosting immune responses most likely through an autophagy-dependent manner in susceptible individuals against infection induced by severe acute respiratory syndrome Coronavirus (SARS‑CoV‑2). Given that STING agonists exert substantial immunomodulatory impacts under a wide array of pathologic conditions, these agents could be considered novel adjuvants for enhancing immunogenicity against the SARS-related coronavirus. Here, we intend to discuss the recent advances in STING agonists' recruitment to boost innate immune responses upon vaccination against SARS-related coronavirus infections. In light of the primordial role of autophagy modulation, the potential of being an antiviral vaccine adjuvant was also explored.
Keywords: Autophagy; COVID-19; Immunogenicity; SARS-CoV-2; Stimulator of interferon gene; Vaccine adjuvant.